Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 17

1.

Colonic delivery of docosahexaenoic acid improves impaired glucose tolerance via GLP-1 secretion and suppresses pancreatic islet hyperplasia in diabetic KK-A(y) mice.

Shida T, Kamei N, Takeda-Morishita M, Isowa K, Takayama K.

Int J Pharm. 2013 Jun 25;450(1-2):63-9. doi: 10.1016/j.ijpharm.2013.04.029. Epub 2013 Apr 22.

PMID:
23618969
2.
3.

The multifaceted potential of glucagon-like peptide-1 as a therapeutic agent.

Lam NT, Kieffer TJ.

Minerva Endocrinol. 2002 Jun;27(2):79-93. Review.

PMID:
11961501
4.

Inhibition of DPP-4: a new therapeutic approach for the treatment of type 2 diabetes.

Pratley RE, Salsali A.

Curr Med Res Opin. 2007 Apr;23(4):919-31. Review.

PMID:
17407649
5.

Dipeptidyl peptidase IV inhibitors for the treatment of impaired glucose tolerance and type 2 diabetes.

Wiedeman PE, Trevillyan JM.

Curr Opin Investig Drugs. 2003 Apr;4(4):412-20. Review.

PMID:
12808880
6.

Therapies for the treatment of type 2 diabetes mellitus based on incretin action.

Gallwitz B.

Minerva Endocrinol. 2006 Jun;31(2):133-47. Review.

PMID:
16682937
7.

Glucagon-like peptide 1 (GLP-1) in the treatment of diabetes.

Nauck MA.

Horm Metab Res. 2004 Nov-Dec;36(11-12):852-8. Review.

PMID:
15655719
8.

Incretins and other peptides in the treatment of diabetes.

Todd JF, Bloom SR.

Diabet Med. 2007 Mar;24(3):223-32. Review.

PMID:
17263764
9.

Potential new approaches to modifying intestinal GLP-1 secretion in patients with type 2 diabetes mellitus: focus on bile acid sequestrants.

Holst JJ, McGill MA.

Clin Drug Investig. 2012 Jan 1;32(1):1-14. doi: 10.2165/11595370-000000000-00000. Review.

PMID:
21958333
10.

Glucagon-like peptide 1 (GLP-1) as a new therapeutic approach for type 2-diabetes.

Nauck MA, Holst JJ, Willms B, Schmiegel W.

Exp Clin Endocrinol Diabetes. 1997;105(4):187-95. Review.

PMID:
9285204
11.

Newly approved and promising antidiabetic agents.

Combettes M, Kargar C.

Therapie. 2007 Jul-Aug;62(4):293-310. Epub 2007 Nov 6. Review.

PMID:
17983555
12.

Glucagon-like peptide 1 and its derivatives in the treatment of diabetes.

Nauck MA, Meier JJ.

Regul Pept. 2005 Jun 15;128(2):135-48. Review.

PMID:
15780433
13.

Glucagon-like peptide analogues for type 2 diabetes mellitus.

Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A.

Cochrane Database Syst Rev. 2011 Oct 5;(10):CD006423. doi: 10.1002/14651858.CD006423.pub2. Review.

PMID:
21975753
14.

GLP-1 in NIDDM.

Holst JJ.

Diabet Med. 1996 Sep;13(9 Suppl 6):S156-60. Review.

PMID:
8894501
15.

The entero-insular axis in type 2 diabetes--incretins as therapeutic agents.

Creutzfeldt W.

Exp Clin Endocrinol Diabetes. 2001;109 Suppl 2:S288-303. Review.

PMID:
11460578
16.

The regulation of function, growth and survival of GLP-1-producing L-cells.

Kuhre RE, Holst JJ, Kappe C.

Clin Sci (Lond). 2016 Jan;130(2):79-91. doi: 10.1042/CS20150154. Review.

PMID:
26637406
17.

Exciting Times for Pancreatic Islets: Glutamate Signaling in Endocrine Cells.

Otter S, Lammert E.

Trends Endocrinol Metab. 2016 Mar;27(3):177-88. doi: 10.1016/j.tem.2015.12.004. Epub 2015 Dec 28. Review.

PMID:
26740469

Supplemental Content

Support Center